Rapamycin Protocols | Working Concentration | Cell Culture | Incubation Time | Treatment

1

T47DAR1 · Cell Viability Assay

Research Field
Oncology
Sample
T47DAR1
Research Purpose
Effect of Rapamycin on resensitization to Alpelisib and resistance to metabolic drugs
Assay
Cell Viability Assay
Culture Conditions
high-glucose DMEM supplemented with 10% fetal bovine serum, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, and 0.4% Amphotericin B (250 μg mL−1) at 37 °C with 5% CO2
Co-treatment / Combination
Alpelisib, concurrent with Rapamycin, 5 days Dichloroacetate, concurrent with Rapamycin, 5 days Metformin, concurrent with Rapamycin, 5 days
Treatment
Rapamycin + Alpelisib / DCA / Metformin
Incubation Time
5 days
Control Setup
Untreated control, single-agent treatments
Results
Rapamycin resensitized Alpelisib-resistant T47DAR1 cells to Alpelisib, but rendered them resistant to metabolic drugs (DCA and Metformin).
Supplementary Fig. 2a
Supplementary Fig. 2a
Supplementary Fig. 2b
Supplementary Fig. 2b
2

T47DAR2 · Cell Viability Assay

Research Field
Oncology
Sample
T47DAR2
Research Purpose
Effect of Rapamycin on resensitization to Alpelisib and resistance to metabolic drugs
Assay
Cell Viability Assay
Culture Conditions
high-glucose DMEM supplemented with 10% fetal bovine serum, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, and 0.4% Amphotericin B (250 μg mL−1) at 37 °C with 5% CO2
Co-treatment / Combination
Alpelisib Metformin Dichloroacetate
Treatment
Rapamycin + Alpelisib, Rapamycin + Metformin, or Rapamycin + Dichloroacetate
Incubation Time
5 days
Control Setup
Untreated control, single-agent treatments
Results
Rapamycin resensitized Alpelisib-resistant T47DAR2 cells to Alpelisib, while rendering them resistant to metabolic drugs such as Metformin and Dichloroacetate.
Supplementary Fig. 2a
Supplementary Fig. 2a
Supplementary Fig. 2b
Supplementary Fig. 2b
3

Primary human cardiac fibroblasts · Western Blot, ELISA

Research Field
Cell Biology
Sample
Primary human cardiac fibroblasts
Research Purpose
Inhibition of IL-11-induced senescence and SASP markers
Assay
Western Blot, ELISA
Culture Conditions
Complete fibroblasts medium-2 supplemented with 5% FBS, 1% fibroblasts growth supplement-2 and 1% penicillin-streptomycin, 37 °C, 5% CO2
Working Concentration
10 nM
Co-treatment / Combination
Recombinant human IL-11 5 ng/mL, concurrent with rapamycin, 24 h
Treatment
IL-11 + Rapamycin
Incubation Time
24 h
Control Setup
Unstimulated control (DMSO), IL-11 alone (with DMSO), IL-11 + U0126 (10 µM)
Results
Rapamycin inhibited IL-11-induced phosphorylation of mTOR and upregulation of p16 and p21, and restored cyclin D1 and PCNA levels. In cell supernatants, rapamycin reduced IL-11-induced IL-6 secretion to ~40 pg/mL (p < 0.0001) and IL-8 secretion to ~1.3 ng/mL (p < 0.0001).
Extended Data Fig. 3a
Extended Data Fig. 3a
Extended Data Fig. 3c
Extended Data Fig. 3c
Extended Data Fig. 3d
Extended Data Fig. 3d
4

Primary human hepatocytes · Western Blot, ELISA

Research Field
Cell Biology
Sample
Primary human hepatocytes
Research Purpose
Inhibition of IL-11-induced senescence and SASP markers by rapamycin in human hepatocytes
Assay
Western Blot, ELISA
Culture Conditions
Hepatocyte medium (5201, ScienCell) containing 2% FBS and 1% penicillin-streptomycin, 37 °C, 5% CO2; serum-starved overnight in basal media prior to stimulation
Seeding Density
4 × 10^5 cells per well in collagen-coated 6-well plate
Working Concentration
10 nM
Co-treatment / Combination
Recombinant human IL-11 10 ng/ml, concurrent with Rapamycin, 24 h
Treatment
Rapamycin + IL-11
Incubation Time
24 h
Control Setup
Untreated/basal control, DMSO vehicle, IL-11 + DMSO, IL-11 + U0126 (10 µM)
Results
Rapamycin prevented IL-11-induced phosphorylation of mTOR, p70S6K, and S6RP, decreased p16 and p21 expression, restored PCNA and cyclin D1 levels, and significantly attenuated IL-11-stimulated secretion of IL-6 (p < 0.0001) and IL-8 (p = 0.0018) in primary human hepatocytes.
Extended Data Fig. 3b
Extended Data Fig. 3b
Extended Data Fig. 3f
Extended Data Fig. 3f
Extended Data Fig. 3g
Extended Data Fig. 3g
5

OT1STAT6-KO CD8+ T cells · Extracellular Flux Analysis, Cell Counting, Flow Cytometry

Research Field
Immunology
Sample
OT1STAT6-KO CD8+ T cells
Research Purpose
Involvement of mTOR pathway in Fc-IL-4-mediated enhancement of glycolysis, proliferation, and effector function in STAT6-deficient OT1 T cells
Assay
Extracellular Flux Analysis, Cell Counting, Flow Cytometry
Culture Conditions
RPMI-1640 supplemented with 10% (v/v) FBS, 1% (v/v) HEPES (pH 7.2–7.5), 1% (v/v) penicillin/streptomycin, 1% (v/v) sodium pyruvate, 0.1% (v/v) 2-mercaptoethanol, 37 °C, 5% CO2
Seeding Density
3×10^5 cells/well in Seahorse culture plate
Working Concentration
100 nM
Co-treatment / Combination
Fc-IL-4 20 ng/mL, concurrent with Rapamycin, 24 h or 48 h dimeric anti-CD3 antibody 0.5 µg/mL, concurrent with Rapamycin, 24 h or 48 h mouse IL-2 10 ng/mL, concurrent with Rapamycin, 24 h or 48 h
Pre-treatment Protocol
Splenocytes from Cas9 knock-in OT1 TCR-transgenic mice were activated with coated anti-CD3 (5 µg/mL) and soluble anti-CD28 (5 µg/mL) in the presence of IL-2 (10 ng/mL) for 1 day, spin-transduced on days 2 and 3 with retrovirus carrying STAT6-targeting gRNA pool (STAT6-1: 5'-CACCGTTGACTTTCCACAACGCCTA-3', STAT6-2: 5'-CACCGAGTTTACTACAGCCCTCGGA-3', STAT6-3: 5'-CACCGATAAAGCGCTGTGAGCGGAA-3'), expanded for 3 days, re-stimulated with dimeric anti-CD3 (0.5 µg/mL) for 2 days to induce PD-1+TIM-3+ CD8+ TTE cells, and sorted before inhibitor treatment
Treatment
Rapamycin + Fc-IL-4
Incubation Time
24 h or 48 h
Control Setup
Untreated/PBS vehicle, Fc-IL-4 alone, WT OT1 control, STAT6-KO without inhibitor
Results
In OT1STAT6-KO CD8+ TTE cells, rapamycin co-treatment completely abolished Fc-IL-4-mediated increases in relative basal ECAR (p < 0.0001), cell counts (p = 0.0002), granzyme B MFI (p < 0.0001), maximal ECAR (p < 0.0001), Glut-1 MFI (p < 0.0001), glucose uptake capacity (p = 0.0224), Bcl-2 MFI (p < 0.0001), CD107a MFI (p = 0.0001), and LDHA expression (p < 0.0001).
Figure 4n
Figure 4n
Figure 4o
Figure 4o
Figure 4p
Figure 4p
Extended Data Fig. 9e
Extended Data Fig. 9e
Extended Data Fig. 9f
Extended Data Fig. 9f
Extended Data Fig. 9g
Extended Data Fig. 9g
Extended Data Fig. 9h
Extended Data Fig. 9h
Extended Data Fig. 9i
Extended Data Fig. 9i
Extended Data Fig. 10c
Extended Data Fig. 10c
6

Ex vivo-induced PMEL CD8+ TTE cells · Flow Cytometry

Research Field
Immunology
Sample
Ex vivo-induced PMEL CD8+ TTE cells
Research Purpose
Involvement of mTOR pathway in Fc-IL-4-mediated metabolic and functional enhancement in PMEL CD8+ TTE cells
Assay
Flow Cytometry
Culture Conditions
complete RPMI medium supplemented with mouse IL-2 (10 ng ml-1), 37 °C
Working Concentration
100 nM
Co-treatment / Combination
dimeric anti-CD3 antibody 0.5 µg ml-1, concurrent with Rapamycin, 24 h mouse IL-2 10 ng ml-1, concurrent with Rapamycin, 24 h Fc-IL-4 20 ng ml-1, concurrent with Rapamycin, 24 h AKT inhibitor VIII (HY-10355) 1 µM, concurrent with Rapamycin, 24 h STAT6 inhibitor (AS1517499) 50 nM, concurrent with Rapamycin, 24 h
Treatment
Rapamycin + Fc-IL-4 + anti-CD3 + IL-2
Incubation Time
24 h
Control Setup
Untreated/vehicle control (PBS), Fc-IL-4 alone, AKT inhibitor VIII (alone or + Fc-IL-4), STAT6 inhibitor AS1517499 (alone or + Fc-IL-4), inhibitor combinations
Results
Inhibition of mTOR by Rapamycin (100 nM), alone or in combination with STAT6 inhibitor, significantly abolished Fc-IL-4-induced upregulation of Glut-1 MFI (p < 0.0001), cell viability (p < 0.0001), CD107a MFI (p = 0.0012), and Granzyme B MFI (p = 0.0014) in ex vivo-induced PMEL CD8+ TTE cells.
Extended Data Fig. 9j
Extended Data Fig. 9j
Extended Data Fig. 9k
Extended Data Fig. 9k
Extended Data Fig. 9l
Extended Data Fig. 9l
Extended Data Fig. 9m
Extended Data Fig. 9m
7

Primary CD8 T cells · Flow Cytometry

Research Field
Immunology
Sample
Primary CD8 T cells
Research Purpose
Effect of acute mTORC1 inhibition on asymmetric c-Myc and CD98 expression in first-division T cells
Assay
Flow Cytometry
Culture Conditions
RPMI 1640 supplemented with 10% (v/v) heat-inactivated FBS, 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 µg/ml streptomycin at 37 °C in 5% CO2
Working Concentration
1 µM
Pre-treatment Protocol
Naïve T cells were labeled with CellTrace Violet and activated on plate-bound anti-CD3 (1 µg/mL), anti-CD28 (1 µg/mL), and recombinant human CD54/ICAM (0.5 µg/mL) for 35 h before compound addition
Treatment
Rapamycin
Incubation Time
45 min
Control Setup
DMSO vehicle control
Results
Acute treatment with rapamycin reduced c-Myc-GFP expression in first-division CD8high T cells to the level of CD8low cells, abolishing c-Myc asymmetry, while CD98 asymmetry remained unaffected (p < 0.05 for c-Myc-GFP in DMSO vs. non-significant under rapamycin).
Figure 3F
Figure 3F
Figure 3G
Figure 3G
8

C57BL/6 mice transferred with sorted first-division c-Myc-GFPhigh or c-Myc-GFPlow OT-I CD8 T cells · Flow Cytometry

Research Field
Immunology
Sample
C57BL/6 mice transferred with sorted first-division c-Myc-GFPhigh or c-Myc-GFPlow OT-I CD8 T cells
Research Purpose
Effect of in vivo mTORC1 inhibition with rapamycin on secondary recall response of transferred c-Mychigh vs c-Myclow CD8 T cells
Assay
Flow Cytometry
Working Concentration
75 ug/kg
Co-treatment / Combination
HKx31-SIINFEKL influenza 10^6 EID50, i.v. infection at day 0 PR8-SIINFEKL influenza, challenge infection 4 weeks post-transfer (after 2 weeks rest), 9 days before harvest
Pre-treatment Protocol
Naïve c-Myc-GFP OT-I CD8 T cells were labeled with Cell Trace Violet, activated in vitro on plate-bound anti-CD3/CD28/ICAM or SIINFEKL-pulsed BMDCs for 36 h, sorted into first-division c-Myc-GFPhigh or c-Myc-GFPlow populations, and 2.5×10^5, 5×10^5, or 7.5×10^5 cells were adoptively transferred i.v. into recipient mice
Treatment
Rapamycin + HKx31-SIINFEKL + PR8-SIINFEKL
Incubation Time
10 days (daily I.P. injections on days 0–10 post primary infection)
Control Setup
PBS vehicle control in c-Myc-GFPhigh recipient mice, c-Myc-GFPlow recipient mice without rapamycin
Results
In PBS-treated controls, c-Myc-GFPlow donor cells generated a significantly higher secondary recall frequency than c-Myc-GFPhigh cells (p=0.0128), whereas in vivo rapamycin administration restored the secondary recall capacity of c-Myc-GFPhigh donor cells to levels equivalent to c-Myc-GFPlow cells (p=0.9726).
Figure 4I
Figure 4I
9

MCF-7 · Fluorescence Microscopy

Research Field
Oncology
Sample
MCF-7
Research Purpose
Induction of autophagy and acidic vesicular organelles
Assay
Fluorescence Microscopy
Culture Conditions
DMEM:F12 supplemented with 10% fetal bovine serum, 5% CO2, 37°C
Seeding Density
1.5 × 10^4 cells/chamber in 4-well chamber slides
Working Concentration
50 nM
Treatment
Rapamycin
Incubation Time
2-days
Control Setup
untreated MCF-7 cells
Results
Treatment of MCF-7 cells with 50 nM rapamycin induced the formation of large monodansylcadaverine (MDC)-positive acidic vesicular organelles, comparable to the induction observed with 8-chloro-adenosine.
Figure 5E
Figure 5E
10

MCF-7 · Flow Cytometry

Research Field
Oncology
Sample
MCF-7
Research Purpose
Induction of autophagy and acidic vesicular organelles
Assay
Flow Cytometry
Culture Conditions
DMEM:F12 supplemented with 10% fetal bovine serum, 5% CO2, 37°C
Working Concentration
50 nM
Treatment
Rapamycin
Incubation Time
3 days
Control Setup
Untreated control, 8-Cl-Ado (10 µM), and bafilomycin A1 (0.1 µg/mL)
Results
Treatment with 50 nM rapamycin for 3 days led to a 14% increase in AVO staining in MCF-7 cells, comparable to the 18% increase observed with 10 µM 8-Cl-Ado.
Figure 5F
Figure 5F
Figure 5G
Figure 5G
11

BT-474 · Flow Cytometry

Research Field
Oncology
Sample
BT-474
Research Purpose
Induction of autophagy and acidic vesicular organelles
Assay
Flow Cytometry
Culture Conditions
DMEM:F12 supplemented with 10% fetal bovine serum, 5% CO2, 37°C
Working Concentration
50 nM
Treatment
Rapamycin
Incubation Time
3 days
Control Setup
Untreated control, 8-Cl-Ado (10 µM), bafilomycin A1 (0.1 µg/mL)
Results
Treatment with 50 nM rapamycin for 3 days caused an approximate 10% increase in AVO staining in BT-474 cells, serving as a positive control comparable to 8-Cl-Ado-mediated autophagy induction.
Figure 5G
Figure 5G
12

Pten-/- zebrafish embryos · Whole-Mount in Situ Hybridization

Research Field
Cell Biology
Sample
Pten-/- zebrafish embryos
Research Purpose
Rescuing expansive myelopoiesis in pten-/- embryos by mTOR inhibition
Assay
Whole-Mount in Situ Hybridization
Culture Conditions
egg water, standard zebrafish maintenance at 28.5 °C
Working Concentration
1, 5, 20 µM
Treatment
Rapamycin
Incubation Time
12 h (from 78 to 90 hpf)
Control Setup
Untreated control embryos, untreated pten-/- embryos, DMSO-treated pten-/- embryos
Results
Rapamycin treatment from 78 to 90 hpf rescued the expansive myelopoiesis phenotype in pten-/- embryos in a dose-dependent manner (Figure 4G-L, N), with 20 µM rapamycin reducing lyz-positive cells per fish to levels below control embryos (p < 0.001).
Figure 4G
Figure 4G
Figure 4H
Figure 4H
Figure 4I
Figure 4I
Figure 4J
Figure 4J
Figure 4K
Figure 4K
Figure 4L
Figure 4L
Figure 4N
Figure 4N
13

Pten-/- (ptena-/- ptenb-/-) zebrafish embryos · Sudan Black Staining

Research Field
Cell Biology
Sample
Pten-/- (ptena-/- ptenb-/-) zebrafish embryos
Research Purpose
Neutrophil maturation rescue
Assay
Sudan Black Staining
Culture Conditions
egg water, 28.5 °C
Working Concentration
5 µM
Treatment
Rapamycin
Incubation Time
12 h
Control Setup
DMSO vehicle-treated pten-/- embryos, DMSO-treated control embryos, rapamycin-treated control embryos
Results
Treatment with 5 µM rapamycin from 78 to 90 hpf largely rescued the maturation block of neutrophils in pten-/- embryos, restoring Sudan Black-positive granulocytes in the CHT to ~70 cells, comparable to control levels.
Figure 5A
Figure 5A
Figure 5B
Figure 5B
Figure 5E
Figure 5E
Figure 5F
Figure 5F
Figure 5G
Figure 5G
14

REH · Flow Cytometry

Research Field
Oncology
Sample
REH
Research Purpose
Cell cycle analysis following rapamycin treatment combined with FAK knockdown
Assay
Flow Cytometry
Culture Conditions
RPMI1640 medium + 10% FBS, CO2 incubator
Working Concentration
100 nM
Pre-treatment Protocol
Lentiviral GFP-FAK shRNA (target sequence: 5′-GGAATGCTTCAAGTGTGCTT-3′, designated FAK X40-2 shRNA) or GFP-empty vector construct transduced into cells, sorted by flow cytometry (FACSAria) 72 h post-transfection for >99% GFP-positive clones before rapamycin treatment
Treatment
Rapamycin
Incubation Time
48 h
Control Setup
REH-empty vector untreated, REH-FAK shRNA untreated, REH-empty vector + rapamycin
Results
Rapamycin alone arrested 65.34 ± 3.62% of REH-empty vector cells in G0/G1 phase, while the combination of rapamycin and FAK shRNA significantly increased G0/G1 arrest to 79.35 ± 3.28% (p < 0.05) with a concomitant decrease in S phase.
Figure 3a
Figure 3a
15

REH · Flow Cytometry

Research Field
Oncology
Sample
REH
Research Purpose
Apoptosis induction
Assay
Flow Cytometry
Culture Conditions
RPMI1640 medium + 10% FBS, 37 °C, CO2 incubator
Working Concentration
100 nM
Pre-treatment Protocol
Lentiviral GFP-FAK shRNA (designated FAK X40-2 shRNA, target sequence 5'-GGAATGCTTCAAGTGTGCTT-3') or GFP-empty vector construct transduced into REH cells, followed by FACS sorting based on GFP expression at 72 h post-transfection until >99% GFP-positive clones were obtained
Treatment
Rapamycin
Incubation Time
30 h
Control Setup
REH-empty vector without rapamycin, REH-empty vector with rapamycin, REH-FAK shRNA without rapamycin
Results
The percentage of Annexin V+ apoptotic cells was significantly elevated in the combination treatment group compared to rapamycin alone (17.50 ± 0.55% vs 9.05 ± 0.41%, p < 0.05).
Figure 3b
Figure 3b
16

REH · Quantitative Real-Time PCR

Research Field
Oncology
Sample
REH
Research Purpose
Apoptosis-related gene expression
Assay
Quantitative Real-Time PCR
Culture Conditions
RPMI1640 medium + 10% FBS, 37 °C, CO2 incubator
Working Concentration
100 nM
Pre-treatment Protocol
FAK knockdown via lentiviral-GFP-FAK-shRNA (designated FAK X40-2 shRNA, target sequence 5'-GGAATGCTTCAAGTGTGCTT-3') or lentiviral GFP-empty vector, followed by repeated FACS sorting at 72 h post-transfection until >99% GFP-positive clones were established before rapamycin treatment
Treatment
Rapamycin
Incubation Time
10 h
Control Setup
REH-empty vector untreated, REH-empty vector + rapamycin, REH-FAK shRNA untreated
Results
Combined treatment significantly promoted mRNA expression of pro-apoptotic genes (PUMA, BMF, BAX; p < 0.05), lowered anti-apoptotic BCL-2 mRNA expression, and yielded a 17.55-fold higher BCL-2/BAX ratio compared to rapamycin alone.
Figure 4
Figure 4
17

NOD/SCID mice · In Vivo Survival Analysis, Complete Blood Count, and Spleen Morphology Analysis

Research Field
Oncology
Sample
NOD/SCID mice
Research Purpose
In vivo therapeutic efficacy, leukemia progression, and survival analysis under rapamycin treatment and FAK knockdown
Assay
In Vivo Survival Analysis, Complete Blood Count, and Spleen Morphology Analysis
Working Concentration
1.5 mg/kg
Pre-treatment Protocol
Five million REH cells stably transduced with GFP-FAK shRNA lentivirus (target sequence 5′-GGAATGCTTCAAGTGTGCTT-3′; designated FAK X40-2 shRNA; sorted by FACSAria for >99% GFP positivity) or GFP-empty vector construct were injected via tail vein into 6- to 8-week-old NOD/SCID mice 10 days before treatment initiation
Treatment
Rapamycin
Incubation Time
7 days
Control Setup
REH-empty vector + DMSO, REH-FAK shRNA + DMSO, REH-empty vector + Rapamycin
Results
In REH-empty vector mice, rapamycin treatment resulted in median survival of 43 days (range 29–52 days, n = 11), whereas in REH-FAK shRNA mice, rapamycin significantly extended median survival to 57 days (range 43–71 days, n = 11; p < 0.05). Combination of rapamycin and FAK shRNA significantly suppressed peripheral WBC counts compared to rapamycin alone (p < 0.01) and reduced splenomegaly measured on day 25.
Figure 5a
Figure 5a
Figure 5b
Figure 5b
Figure 5c
Figure 5c
18

Primary murine MLL-AF9 GFP+ AML cells · Flow Cytometry

Research Field
Oncology
Sample
Primary murine MLL-AF9 GFP+ AML cells
Research Purpose
Effect of rapamycin on apoptosis and mTORC1 signaling in Rheb1fl/fl AML cells
Assay
Flow Cytometry
Culture Conditions
IMDM + 10% FBS, 50 ng/ml mSCF, 10 ng/ml mIL-6, 10 ng/ml mIL-3
Seeding Density
4×10^4 cells/well in 24-well plate
Working Concentration
5.45 nM/ml
Treatment
Rapamycin
Incubation Time
48 h
Control Setup
Absolute ethanol vehicle (mock treatment)
Results
In Rheb1fl/fl GFP+ AML cells, rapamycin treatment significantly increased the percentage of apoptotic cells compared with vehicle control (p < 0.01) and markedly suppressed mTORC1 signaling as shown by decreased normalized MFI of p-S6 (p < 0.001) and p-4E-BP1 (p < 0.001).
Figure 5e
Figure 5e
Figure 5f
Figure 5f
19

Primary murine MLL-AF9 GFP+ AML cells (Rheb1Δ/Δ) · Flow Cytometry

Research Field
Oncology
Sample
Primary murine MLL-AF9 GFP+ AML cells (Rheb1Δ/Δ)
Research Purpose
Effect of rapamycin on apoptosis and mTORC1 signaling in Rheb1-deficient AML cells
Assay
Flow Cytometry
Culture Conditions
IMDM + 10% FBS, 50 ng/ml mSCF, 10 ng/ml mIL-6, 10 ng/ml mIL-3
Seeding Density
4×10^4 cells/well in 24-well plate
Working Concentration
5.45 nM/ml
Treatment
Rapamycin
Incubation Time
48 h
Control Setup
Absolute ethanol vehicle (mock treatment)
Results
In Rheb1Δ/Δ GFP+ AML cells, rapamycin treatment significantly increased the percentage of apoptotic cells to ~44% compared to ~26% in vehicle-treated Rheb1Δ/Δ cells, while further reducing normalized MFI of p-S6 and p-4E-BP1 compared to vehicle-treated Rheb1Δ/Δ cells (p < 0.001 and p < 0.01).
Figure 5e
Figure 5e
Figure 5f
Figure 5f
20

BALB/c nu/nu mice · Histological Analysis and Immunohistochemistry

Research Field
Oncology
Sample
BALB/c nu/nu mice
Research Purpose
In vivo effect of rapamycin on Ube2v1-mediated lung metastasis
Assay
Histological Analysis and Immunohistochemistry
Working Concentration
5 mg/kg
Pre-treatment Protocol
SW480 cells stably overexpressing Ube2v1 (using GV218 lentiviral vector selected with 1 mg/ml puromycin; Genechem) or vector control cells (1 × 10^7 cells in 0.2 ml) injected into the lateral tail vein of 6-week-old BALB/C-nu mice
Treatment
Rapamycin
Incubation Time
2 weeks
Control Setup
Vector control, Ube2v1 overexpression alone
Results
Administration of rapamycin significantly reduced the lung index and surface metastatic nodule numbers in mice injected with Ube2v1-overexpressing SW480 cells (p < 0.05), while restoring Beclin1 and E-cadherin expression in lung metastases.
Figure 5c
Figure 5c
Figure 5d
Figure 5d
Figure 5e
Figure 5e
Figure 5f
Figure 5f